Dimension Inx, a Chicago, IL-based biomaterials platform company, raised $12M in Series A funding.
The round was led by Prime Movers Lab (PML), with participation from KdT Ventures and Revolution’s Rise of the Rest Seed Fund (ROTR), Solas BioVentures, Portal Innovation Ventures, and Alumni Ventures.
The company intends to use the funds to advance the development of its therapeutics focused on functional organ restoration, and expand its manufacturing capabilities. In the near term, the company will use the funds to support the commercial launch of their first product, CMFlex™.
Led by CEO Caralynn Nowinski Collens, Dimension Inx is a biomaterials platform that designs, develops, and manufactures therapeutic products. The company works with biotech and medical device partners to help solve materials problems, and internally develop medical products for various therapeutic applications ranging from bone regeneration to fertility preservation.
In addition to its Series A funding, Dimension Inx receives U.S. FDA 510(k) for CMFlex™, the first 3D-printed regenerative product cleared by the FDA.
FinSMEs